TEMENOS
16.6.2020 09:09:06 CEST | Business Wire | Press release
Intelligence Sales League Table 2020 (SLT) . Temenos was also named a regional leader in both Europe and Americas. Temenos, with its AI and advanced cloud technology, continues to be the undisputed leader in the main product categories in the IBS League Table with the greatest number of competitors.
Temenos has been ranked as the best-selling core banking system for 15 years, as well as the best-selling vendor for digital banking for the fourth consecutive year. For 21 years running, Temenos has demonstrated consistent leadership, placing in the top two positions for core banking systems. In this year’s Sales League Table, Temenos led in nine categories, including:
- #1 Digital banking and channels with Temenos Infinity, gaining 38 new name deals
- #1 Best-selling core banking system with Temenos Transact, securing 51 new name customer deals
- #1 Retail payments system with 51 new deals for Temenos Payments
- #1 Risk management system, closing 53 new deals with Temenos Financial Crime Mitigation
- #1 Regional Leader in Europe, working with ABN AMRO and challenger banks such as Lunar and Alba
- #1 Regional Leader in Americas, partnering with innovative banks such as CWB Financial Group
- #2 Regional Leader in the Middle-East and Africa with key clients such as Egyptian National Post Organization
- #2 Regional Leader in APAC with innovative clients such as TSB with Temenos Infinity Digital Onboarding and Virgin Money Australia
- #2 Islamic Banking, partnering with the world's largest Islamic bank, Al Rajhi Bank
Max Chuard, Chief Executive Officer, Temenos, said: “It’s a great honor to be recognized as the best-selling banking software provider with the most modern technology across the main product categories of digital, core banking, retail payments, and risk management systems. Now more than ever we see an acceleration in digital and cloud adoption – banks need agile, modern banking technology across the front and back office. We offer our offer our clients, both established banks and new entrants, the winning combination of the richest banking functionality and the most advanced cloud-native, cloud-agnostic technology. We deliver solutions for the ‘New Normal’ that give our clients agility, speed to market, hyper-personalized services at the front end and automation and operational excellence in the back office. The IBS report reconfirms Temenos as global powerhouse and the world’s #1 banking software company and I would like to thank our customers, partners and employees for helping us achieve this exciting milestone.”
IBS’ Sales League Table Panel, said: “2019 was a record-breaking year for our Sales League Table, with nearly 900 validated deals globally and the highest level of vendor participation to-date. Temenos’ success was notable due to achieving #1 positions in the most intensely competitive categories including digital banking, core banking, retail payments and risk management systems. At IBS Intelligence, we are seeing banks re-visiting their digital transformation plans to support their businesses through the current COVID-19 crisis. 2020 will be an interesting year for our industry and we will be continuing to track new deals and trends to support our clients worldwide.”
Temenos continues to relentlessly focus on innovation, investing 20% of its revenue in R&D – more than any other provider in the industry. The IBS Intelligence Sales League Table is the global barometer for sales performance of banking platforms ranging from retail, to private, to Islamic, to digital-only and universal banking. The SLT provides a vital tool to executives in banks for selecting vendors for RFIs and influences vendor selection across conventional and digital banking.
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005373/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom